A Study in Patients With Type 2 Diabetes Mellitus (IMAGINE 2)
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study
Sponsor: Eli Lilly and Company
Listed as NCT01435616, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Ampelokipoi, Greece , Anniston, United States , Athens, Greece , Athens, United States , Atlanta, United States , Auckland, New Zealand , Austin, United States , Bangor, United States , Beaver, United States and 156 more locations